ImmunityBio: Q3 Product Revenue Increases 53% To $48.7 Million
· pulse2.com · popularity 15/100 · 0 similar stories today
Read the original at pulse2.com →
Summary
ImmunityBio reported third-quarter 2026 net product revenue of $48.7 million, an increase of 53% year over year, as adoption of ANKTIVA expanded among U.S. urologists. Net product revenue for the first nine months reached $143.6 million, up 92% and above the $113 million generated during all of 2025. The post ImmunityBio: Q3 Product Revenue Increases 53% To $48.7 Million appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 20.